Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Curtis Triplitt

Showing results (31-40 of 58) with videos related to

Pageof 6
Sort By:
Diabetes Care|October 3, 2007
Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanismsMarianella Fernandez, Curtis Triplitt, Estela Wajcberg, et al.
BMJ Open Diabetes Research & Care|April 27, 2025
Glycemic and non-glycemic benefits of initial triple therapy versus sequential add-on therapy in patients with new-onset diabetes: results from the EDICT studyMuhammad Abdul-Ghani, Curtiss Puckett, Siham Abdelgani, et al.
Diabetes Care|December 4, 2020
Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICTMuhammad Abdul-Ghani, Curtiss Puckett, John Adams, et al.
Diabetes Care|January 19, 2017
Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar StudyMuhammad Abdul-Ghani, Osama Migahid, Ayman Megahed, et al.
Diabetes Care|June 16, 2017
Erratum. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. Diabetes Care 2017;40:325-331Muhammad Abdul-Ghani, Osama Migahid, Ayman Megahed, et al.
Diabetes Care|October 27, 2006
Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylureaCurtis Triplitt, Leonard Glass, Yoshiniro Miyazaki, et al.
Diabetes, Obesity & Metabolism|November 28, 2024
Effect of dapagliflozin on renal haemodynamics in hyperfiltering T2D patientsEugenio Cersosimo, Qin YueJuan, Gozde Baskoy, et al.
Diabetes|April 22, 2017
Empagliflozin and Kinetics of Renal Glucose Transport in Healthy Individuals and Individuals With Type 2 DiabetesHussein Al-Jobori, Giuseppe Daniele, Eugenio Cersosimo, et al.
American Journal of Physiology. Endocrinology and Metabolism|March 13, 2008
Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetesAntonio Cervera, Estela Wajcberg, Apiradee Sriwijitkamol, et al.
Diabetes Care|March 30, 2020
Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA<sub>1c</sub>, in Patients With Type 2 DiabetesAli Muhammed Ali, Robert Martinez, Hussein Al-Jobori, et al.
Pageof 6

Showing results (31-40 of 58) with videos related to

Sort By:
Pageof 6
Diabetes Care|October 3, 2007
Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanismsMarianella Fernandez, Curtis Triplitt, Estela Wajcberg, et al.
BMJ Open Diabetes Research & Care|April 27, 2025
Glycemic and non-glycemic benefits of initial triple therapy versus sequential add-on therapy in patients with new-onset diabetes: results from the EDICT studyMuhammad Abdul-Ghani, Curtiss Puckett, Siham Abdelgani, et al.
Diabetes Care|December 4, 2020
Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICTMuhammad Abdul-Ghani, Curtiss Puckett, John Adams, et al.
Diabetes Care|January 19, 2017
Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar StudyMuhammad Abdul-Ghani, Osama Migahid, Ayman Megahed, et al.
Diabetes Care|June 16, 2017
Erratum. Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. Diabetes Care 2017;40:325-331Muhammad Abdul-Ghani, Osama Migahid, Ayman Megahed, et al.
Diabetes Care|October 27, 2006
Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylureaCurtis Triplitt, Leonard Glass, Yoshiniro Miyazaki, et al.
Diabetes, Obesity & Metabolism|November 28, 2024
Effect of dapagliflozin on renal haemodynamics in hyperfiltering T2D patientsEugenio Cersosimo, Qin YueJuan, Gozde Baskoy, et al.
Diabetes|April 22, 2017
Empagliflozin and Kinetics of Renal Glucose Transport in Healthy Individuals and Individuals With Type 2 DiabetesHussein Al-Jobori, Giuseppe Daniele, Eugenio Cersosimo, et al.
American Journal of Physiology. Endocrinology and Metabolism|March 13, 2008
Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetesAntonio Cervera, Estela Wajcberg, Apiradee Sriwijitkamol, et al.
Diabetes Care|March 30, 2020
Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA<sub>1c</sub>, in Patients With Type 2 DiabetesAli Muhammed Ali, Robert Martinez, Hussein Al-Jobori, et al.
Pageof 6